Riociguat Impurity 11 NEW

Riociguat Impurity 11

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

Product Information

• Product Number: R018011

• English Name: Riociguat Impurity 11

• English Alias: 6-amino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-7-methyl-7H-purin-8(9H)-one

• CAS Number: 1361569-18-7

• Molecular Formula: C₁₉H₁₅FN₈O

• Molecular Weight: 390.37

Advantages

• Well-defined with distinct polyheterocyclic features: Contains purine ring (6-amino, 8-keto, 7-methyl substituted), pyrazolo[3,4-b]pyridine ring, and 2-fluorobenzyl side chain. Unlike riociguat (soluble guanylate cyclase activator with pyrimidine ring), its keto group polarity, fluorine electronegativity, and polyheterocyclic conjugation create significant differences, enabling precise differentiation via HPLC/SFC as a specific marker;

• High stability and traceability: Rigid polyheterocyclic (purine, pyrazolopyridine) structures and stability of amide bonds ensure neutral-condition stability. As a byproduct from incomplete purine ring oxidation or cyclization in riociguat synthesis, it directly reflects heterocyclic construction selectivity, improving process tracing accuracy;

• High detection sensitivity: Polyheterocyclic conjugation shows strong UV absorption (250-290nm), combined with m/z 391 [M+H]⁺ enabling ppb-level analysis via LC-MS, compatible with soluble guanylate cyclase activator heterocyclic impurity systems.

Applications

• Pharmaceutical quality control: Used as an impurity reference standard to quantify Riociguat Impurity 11 in APIs, ensuring residual purine-derived impurities meet quality standards;

• Synthesis optimization: Optimizing heterocyclic construction conditions (oxidant selection) by monitoring impurity levels to enhance target pyrimidine ring specificity and reduce purine byproducts;

• Intermediate purity assessment: Evaluating purity of key heterocyclic intermediates in riociguat synthesis to support subsequent side chain modification.

Background Description

Research Status

• Analytical method validation: Developing HPLC assays with C18 columns for separation, achieving 0.1 ppb detection limits;

• Cyclization mechanism: Studying impurity formation kinetics under varying cyclization reagents to clarify purine-pyrimidine isomerization pathways;

• Control strategies: Using selective cyclization catalysts to keep impurity levels below 0.1% and enhance API purity;

• Structural confirmation: Using ¹H/¹³C/¹⁹F-NMR to verify purine structure and substitution positions, distinguishing from riociguat for authoritative identification.

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com